Cargando…
Dasatinib-Induced Chylothorax: A Clinical Laboratory’s Perspective
Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis...
Autores principales: | Martínez, Rafael J. García, Gea, Clara Sanz, Martin-Riera, Víctor, Ruiz, Armando Raúl Guerra, Barzanti, Rosanna Paciucci, Ferrer-Costa, Roser, Ramirez-Serra, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Communications and Publications Division (CPD) of the IFCC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131239/ https://www.ncbi.nlm.nih.gov/pubmed/37124659 |
Ejemplares similares
-
Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015) -
DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019) -
A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022) -
Dasatinib-induced pleural effusion: Chylothorax, an option to consider
por: Ferreiro, Lucía, et al.
Publicado: (2016) -
Dasatinib: Chylothorax and right pleural effusion: case report
Publicado: (2019)